Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

TScan Therapeutics, a US-based T-cell immunotherapy developer spun out of Harvard University, has filed for an initial public offering on the Nasdaq Global Market.
The company has set a placeholder figure of $100m. Morgan Stanley, Jefferies, Cowen and Barclays Capital are underwriters for the IPO.
Founded in 2018, TScan is developing T-cell therapies to target haematological and solid tumours. Its TargetScan tool analyses cancer patients’ active T-cell receptors to genetically replicate them through its ReceptorScan technology.
…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in